{"title":"从护理人员和医生的角度看vosoritide在软骨发育不全治疗中的作用:对Mary Andrews和Melita Irving的采访","authors":"M. Irving, Mary Andrews","doi":"10.2217/frd-2023-0002","DOIUrl":null,"url":null,"abstract":"Mary Andrews is one of the co-founders of The MAGIC Foundation (IL, USA) and Melita Irving is a clinical geneticist from Guy’s and St Thomas’ NHS Foundation Trust (London, UK) and they are speaking with Rachel Jenkins (Publishing Manager) about achondroplasia and approved treatment, vosoritide. They discuss the impact vosoritide will have on unmet needs in the treatment for achondroplasia.","PeriodicalId":432772,"journal":{"name":"Future Rare Diseases","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A caregiver and physician perspective on the role of vosoritide in the treatment of achondroplasia: an interview with Mary Andrews and Melita Irving\",\"authors\":\"M. Irving, Mary Andrews\",\"doi\":\"10.2217/frd-2023-0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mary Andrews is one of the co-founders of The MAGIC Foundation (IL, USA) and Melita Irving is a clinical geneticist from Guy’s and St Thomas’ NHS Foundation Trust (London, UK) and they are speaking with Rachel Jenkins (Publishing Manager) about achondroplasia and approved treatment, vosoritide. They discuss the impact vosoritide will have on unmet needs in the treatment for achondroplasia.\",\"PeriodicalId\":432772,\"journal\":{\"name\":\"Future Rare Diseases\",\"volume\":\"34 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Rare Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/frd-2023-0002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Rare Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/frd-2023-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Mary Andrews是the MAGIC Foundation (IL, USA)的联合创始人之一，Melita Irving是Guy ' s and St Thomas NHS Foundation Trust (London, UK)的临床遗传学家，他们正在与Rachel Jenkins(出版经理)讨论软骨发育不全和已批准的治疗方法vosoritide。他们讨论了vosoritide对软骨发育不全治疗中未满足需求的影响。
A caregiver and physician perspective on the role of vosoritide in the treatment of achondroplasia: an interview with Mary Andrews and Melita Irving
Mary Andrews is one of the co-founders of The MAGIC Foundation (IL, USA) and Melita Irving is a clinical geneticist from Guy’s and St Thomas’ NHS Foundation Trust (London, UK) and they are speaking with Rachel Jenkins (Publishing Manager) about achondroplasia and approved treatment, vosoritide. They discuss the impact vosoritide will have on unmet needs in the treatment for achondroplasia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
